Education
About Us
Working with TipRanks
Follow Us
XHS - ETF AI Analysis
Top Page
SPDR S&P Health Care Services ETF (XHS)
Rating:66Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid returns over the past three months and year-to-date, indicating positive momentum.
Focused Sector Exposure
The fund’s heavy allocation to the Health Care sector provides targeted exposure to a resilient and essential industry.
Reasonable Expense Ratio
The ETF charges a relatively low expense ratio, making it cost-effective compared to actively managed funds.
Negative Factors
Underperforming Top Holdings
Several of the largest positions, such as NeoGenomics and Acadia Healthcare, have struggled with weak year-to-date performance.
High Sector Concentration
With over 96% of assets in Health Care, the fund is highly exposed to risks specific to this sector.
Limited Geographic Diversification
The ETF is almost entirely focused on U.S. companies, leaving investors vulnerable to domestic market fluctuations.
XHS vs. SPDR S&P 500 ETF (SPY)
AUM87.12M
RegionNorth America
Expense Ratio0.35%
Beta0.58
IssuerSPDR
Inception DateSep 28, 2011
Dividend Yield0.23%
Asset ClassEquity
Index TrackedS&P Health Care Services Select Industry
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,717
30 Day Avg. Volume7,154
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
127.95Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering61
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XHS Summary
The SPDR S&P Health Care Services ETF (XHS) focuses on companies in the health care sector, specifically Health Care Providers & Services. It includes businesses like hospitals, outpatient services, and managed health care. Some well-known companies in this ETF are CVS Health and McKesson. This ETF might appeal to investors looking for growth and stability, as health care is a fundamental need and demand is expected to rise with an aging population. However, new investors should be aware that the ETF’s performance can fluctuate with changes in the health care industry, such as regulatory shifts or market trends.
How much will it cost me?The SPDR S&P Health Care Services ETF (XHS) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which typically requires more active management compared to broad-market index funds.
What would affect this ETF?The SPDR S&P Health Care Services ETF (XHS) could benefit from increasing demand for health care services driven by an aging population and advancements in medical technology, which support innovation and growth in its top holdings like NeoGenomics and Guardant Health. However, potential risks include regulatory changes or shifts in government health care policies that could impact profitability, as well as broader economic conditions that may affect consumer spending on health care services. With its strong focus on U.S.-based health care providers, the ETF is well-positioned to capitalize on the sector's resilience but remains sensitive to policy and economic fluctuations.
XHS Top 10 Holdings
The SPDR S&P Health Care Services ETF (XHS) is heavily concentrated in U.S. health care providers, with names like Guardant Health and PACS Group Inc. driving recent gains thanks to strong technical momentum and positive earnings sentiment. However, NeoGenomics has been a drag on performance, struggling with profitability issues despite clinical revenue growth. Cardinal Health and McKesson offer steady contributions, buoyed by robust cash flow and strategic focus, though high leverage tempers their outlook. Overall, the fund leans into the resilience of health care services, but mixed results from key holdings highlight the sector’s challenges.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Guardant Health | 3.29% | $2.91M | $13.12B | 193.64% | 61 Neutral | |
| PACS Group Inc | 3.21% | $2.84M | $5.23B | 116.61% | 66 Neutral | |
| NeoGenomics | 2.57% | $2.28M | $1.52B | -33.16% | 55 Neutral | |
| Brookdale Senior Living | 2.46% | $2.18M | $2.43B | 94.88% | 61 Neutral | |
| Cardinal Health | 2.44% | $2.16M | $47.12B | 67.81% | 66 Neutral | |
| Centene | 2.37% | $2.10M | $19.89B | -31.25% | 58 Neutral | |
| BrightSpring Health Services, Inc. | 2.35% | $2.08M | $6.47B | 93.43% | 67 Neutral | |
| GeneDx Holdings | 2.31% | $2.05M | $4.49B | 116.48% | 68 Neutral | |
| Select Medical | 2.27% | $2.01M | $1.91B | -20.84% | 70 Outperform | |
| HCA Healthcare | 2.24% | $1.99M | $110.07B | 54.42% | 70 Neutral |
XHS Technical Analysis
Positive
―
Price Trends
104.63
Positive
100.46
Positive
98.42
Positive
Market Momentum
1.29
Positive
63.65
Neutral
58.60
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XHS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 106.87, equal to the 50-day MA of 104.63, and equal to the 200-day MA of 98.42, indicating a bullish trend. The MACD of 1.29 indicates Positive momentum. The RSI at 63.65 is Neutral, neither overbought nor oversold. The STOCH value of 58.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XHS.
XHS Peer Comparison
Comparison Results
Performance Comparison
XHS
SPDR S&P Health Care Services ETF
109.60
15.56
16.55%
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents